Sarah Cannon Research Institute | Strategic Alliance Partners

October 06, 2022

Melissa L. Johnson, MD, expands on the updated data from the POSEIDEN trial, the rationale for investigating the combination, and what these results mean for the treatment of metastatic non–small cell lung cancer.

October 05, 2022

Melissa L. Johnson, MD, discusses the evolution of frontline treatment in non–small cell lung cancer.

September 12, 2022

Ribociclib plus endocrine therapy elicited statistically significant progression-free survival and overall survival benefits vs placebo plus endocrine therapy in patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases, including those with liver metastases and multiple metastatic sites.

September 11, 2022

The frontline combination of tremelimumab plus durvalumab and chemotherapy generated a long-term overall survival benefit in patients with metastatic non–small cell lung cancer.

August 10, 2022

Erika P. Hamilton, MD, discusses testing used to identify patients with HER2-positive and HER2-low breast cancer.

July 30, 2022

Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of expression.

July 12, 2022

Benjamin Garmezy, MD, discussed the positive trajectory of antibody-drug conjugates and immunotherapy in urothelial carcinoma, highlighting the importance of considering individual patient eligibility for treatments like first-line chemotherapy.

June 23, 2022

HPN328, a novel half-life extended DLL3-targeting T-cell engager, demonstrated clinical activity and tolerability in patients with pretreated small cell lung cancer and other neuroendocrine tumors, according to findings from a phase 1/2 study (NCT04471727).

June 14, 2022

Erika P. Hamilton, MD, discusses the updated analysis of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative breast cancer.

June 04, 2022

Updated data from a safety analysis of the phase 3 DESTINY-Breast03 study confirmed the tolerability of trastuzumab deruxtecan among patients with with HER2-positive unresectable or metastatic breast cancer.

May 09, 2022

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

April 25, 2022

The novel allogeneic CAR-engineered natural killer cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia and non-Hodgkin lymphoma.

April 05, 2022

David Spigel, MD, discusses potential upcoming developments in targeted therapies for non–small cell lung cancer.

February 22, 2022

Investigators hope to address the need for additional treatment options for patients with class II or class III BRAF-altered disease with KIN-2787, a next-generation, orally available, potent, and selective small molecule inhibitor.

February 15, 2022

The survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly three decades, thanks in large part to scientific discoveries and treatment advances.

February 11, 2022

Meredith McKean, MD, MPH, discusses the importance of molecular profiling in melanoma.

February 09, 2022

Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.

January 09, 2022

David Spigel, MD, discussed the focus of each presentation, which centered on immunotherapy vs chemoimmunotherapy in the frontline metastatic setting, the surgical perspective of treatment in early-stage NSCLC, best practices for molecular testing, and EGFR- and KRAS-targeted therapies for patients with advanced disease.

January 08, 2022

One of the reverberating themes of 2021 that should carry into 2022 is the importance of molecular testing.

December 29, 2021

The shift away from accepting only positive overall survival (OS) data from phase 3 trials as the pathway toward regulatory approval has been the biggest takeaway from 2021 in lung cancer.